GENFIT Announces First Patient First Visit for the Evaluation of NTZ in Subjects with Hepatic Impairment as part of its ACLF ProgramGlobeNewsWire • 11/09/21
New Clinical Data on GENFIT's Investigational Compound Elafibranor to be Presented at AASLD The Liver Meeting®GlobeNewsWire • 11/02/21
GENFIT Reports First Half-Year 2021 Financial Results and Provides Corporate UpdateGlobeNewsWire • 09/29/21
GENFIT obtains non-dilutive financing of €11 million in the form of a State Guaranteed LoanGlobeNewsWire • 06/24/21
GENFIT presents new NIS4® data in NASH at the International Liver Congress™ and the 81st Scientific Sessions of the American Diabetes AssociationGlobeNewsWire • 06/23/21
GENFIT: June 15, 2021 Combined Shareholders Meeting: Wide support for the resolutions submitted to the shareholders' vote but quorum not met on first conveningGlobeNewsWire • 06/15/21
GENFIT Informs its Shareholders of Certain Procedures for the Combined General Meeting of June 15, 2021GlobeNewsWire • 05/27/21
GENFIT Annual Combined General Meeting of June 15, 2021 - Availability of Preparatory DocumentsGlobeNewsWire • 05/10/21
GENFIT: Publication of the 2020 Universal Registration Document and the 2020 Annual Report on Form 20-F; Annual Shareholders Meeting to take place on June 15, 2021GlobeNewsWire • 04/23/21
GENFIT hires Thomas Baetz as Chief Financial Officer and adds two new members to its Executive CommitteeGlobeNewsWire • 04/22/21
GENFIT Reports Full-Year 2020 Financial Results and Provides Corporate UpdateGlobeNewsWire • 04/01/21
GENFIT Announces Publication of Positive Results from the Phase 2 Clinical Trial Evaluating Elafibranor in Patients with PBC in the Journal of HepatologyGlobeNewsWire • 02/09/21
GENFIT: Technical Corrections to the Results of the January 25, 2021 Bondholders Meeting with No Impact on Resolutions' ApprovalGlobeNewsWire • 01/27/21